Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (70)	7/15/1999 1:37:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

This is helping to bring back into focus my perception of what Gene Logic is all about: I should have listened to it before I blurted out those two posts... Listen to Gene Logic's presentation at First Informed Investors Atlanta Health Care Stocks Forum genelogic.com (somehow I missed this back in March, or just forgot to go back and listen after it came up) vcall link: vcall.com What I took from this, at least on the first listen, was that the Flow-Through chip's sensitivity, becuase of the increased surface area, might be the most important thing to keep in mind, the re-usability is nice too. The chip needs to be proven now.

To: Mike McFarland who wrote (70)	9/9/1999 2:53:00 PM
From: Steve Push	Read Replies (2) \| Respond to of 360

<<I see from this year's annual report that one of the goals of Gene Logic is to begin using the Flow-Through chip--screening for leads. I think I asked this once before, but I will again: Where does Gene Logic get the library of compounds from which to find candidates?>> The chip is still in development. We have not done any screening yet. If we were to successfully develop the chip for this purpose, the customer (i.e., pharmaceutical company) would be expected to supply the library. The paragraph above contains forward-looking statements about the potential use of the Flow-thru Chip(TM) microarray in screening for lead compounds. Such statements reflect management's current view of future events. Actual results may differ materially from these projections because of a number of factors, including risks related to technological challenges, competition, the cost-effectiveness of the technology, and the degree to which pharmaceutical companies use gene expression information in their drug discovery programs. These risk factors and others are more fully described in the company's Annual Report on Form 10-K for the year ended December 31, 1998, and other documents filed with the Securities and Exchange Commission. Steve Push Vice President, Corporate Communications Gene Logic Inc. Note: I participate occasionally on this message board as an official company spokesperson. Because of time constraints, however, I cannot respond to all questions. My failure to comment on or respond to someone else's message implies neither agreement nor disagreement with the information in that message. Past messages that I have posted may now contain out-of-date information. To be certain that you have the latest information about Gene Logic, please read recent press releases, SEC filings, and other documents available on our Web site (http://www.genelogic.com).